Ludvik, Bernhard

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 850

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 639

Sleeve Gastrectomy as Sole and Definitive Bariatric Procedure: 5-Year Results for Weight Loss and Ghrelin

Bohdjalian, A., Langer, F. B., Shakeri-Leidenmühler, S., Gfrerer, L., Ludvik, B., Zacherl, J., & Prager, G. (2010) · Obesity Surgery

Bariatric Surgery and OutcomesBody Contouring and Surgery

Cited by 503

The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus

Cauza, E., Hanusch-Enserer, U., Strasser, B., Ludvik, B., Metz-Schimmerl, S., Pacini, G., Wagner, O., Georg, P., Prager, R., Kostner, K., et al. (2005) · Archives of Physical Medicine and Rehabilitation

Cardiovascular and exercise physiologyPhysical Activity and Health

Cited by 392

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 376

Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global HAT study

Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2016) · Diabetes Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 276

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 266

Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans

Hartter, E., Svoboda, T., Ludvik, B., Schuller, M., Lell, B., Kuenburg, E., Brunnbauer, M., Woloszczuk, W., & Prager, R. (1991) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 191

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial

von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes and associated disordersPancreatic function and diabetes

Cited by 186

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet

Peripheral Artery Disease ManagementDiabetes Treatment and Management

Cited by 176

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery

Krzizek, E.-C., Brix, J. M., Herz, C. T., Kopp, H. P., Schernthaner, G.-H., Schernthaner, G., & Ludvik, B. (2018) · Obesity Surgery

Bariatric Surgery and OutcomesNutrition and Health in Aging

Cited by 99

Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes

Ludvik, B., Lell, B., Hartter, E., Schnack, C., & Prager, R. (1991) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 82

Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes

Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters-Weijnen, C., Forsén, T., Galstyan, G., Geelhoed-Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2017) · Diabetes Research and Clinical Practice

Diabetes Management and ResearchDiabetes Management and Education

Cited by 71

Reduction of both number and proliferative activity of human endothelial progenitor cells in obesity

Tobler, K., Freudenthaler, A., Baumgartner-Parzer, S. M., Wolzt, M., Ludvik, B., Nansalmaa, E., Nowotny, P. J., Seidinger, D., Steiner, S., Luger, A., et al. (2010) · International Journal of Obesity

Angiogenesis and VEGF in CancerAdipokines, Inflammation, and Metabolic Diseases

Cited by 59

Alterations in Gastrointestinal, Endocrine, and Metabolic Processes After Bariatric Roux-en-Y Gastric Bypass Surgery

Anderwald, C.-H., Tura, A., Promintzer-Schifferl, M., Prager, G., Stadler, M., Ludvik, B., Esterbauer, H., Bischof, M. G., Luger, A., Pacini, G., et al. (2012) · Diabetes Care

Bariatric Surgery and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 51

Feasibility and efficacy of an isocaloric high-protein vs. standard diet on insulin requirement, body weight and metabolic parameters in patients with type 2 diabetes on insulin therapy

Luger, M., Holstein, B., Schindler, K., Kruschitz, R., & Ludvik, B. (2013) · Experimental and Clinical Endocrinology & Diabetes

Diabetes Treatment and ManagementDiet and metabolism studies

Cited by 45

A pilot study of mobile phone-based therapy for obese patients

Morak, J., Schindler, K., Goerzer, E., Kastner, P., Toplak, H., Ludvik, B., & Schreier, G. (2008) · Journal of Telemedicine and Telecare

Mobile Health and mHealth ApplicationsTelemedicine and Telehealth Implementation

Cited by 40

β-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects

Kautzky-Willer, A., Thomaseth, K., Clodi, M., Ludvik, B., Waldhäusl, W., Prager, R., & Pacini, G. (1996) · Metabolism

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35